Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, but US funding cuts could soon reverse that progress.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January ...

HIV/AIDS-related deaths have fallen to their lowest level in more than 40 years as a result of the fight against the virus.

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, in part due to efforts to fight HIV. But U ...